This is a retrospective cohort study aiming to collect data on patients' characteristics, resource utilization, adverse events management and calculate costs attributed to current treatments of advance RCC patients who have received at least one prior VEGF-targeted therapy in Taiwan from National Health Insurance (NHI) perspective.
Study Type
OBSERVATIONAL
Enrollment
28
National Taiwan University Hospital
Taipei, Taiwan
Taipei Veterans General Hospital
Taipei, Taiwan
Medication usage
Time frame: From start point for 2.5 months
Treatment's duration
Time frame: From start point for 2.5 months
Cost of medication used
Time frame: From start point for 2.5 months
Costs of adverse event management
(total calculated costs attributed to Adverse Effects (AEs) management according to the attached list of adverse events
Time frame: From start point for 2.5 months
Frequency of health resource usage
Outpatient department visits, CT scan, blood test number and types
Time frame: From start point for 2.5 months
Cost of health resource usage
Outpatient department visits, CT scan, blood test number and types
Time frame: From start point for 2.5 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.